[{"orgOrder":0,"company":"Windward Bio","sponsor":"OrbiMed","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Antibody","year":"2025","type":"Series A Financing","leadProduct":"HBM-9378","moa":"TSLP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Windward Bio","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.20000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Windward Bio \/ OrbiMed","highestDevelopmentStatusID":"6","companyTruncated":"Windward Bio \/ OrbiMed"}]

Find Clinical Drug Pipeline Developments & Deals by Windward Bio

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : The financing aims to advance the clinical development of WIN378 (HBM-9378), which is being evaluated for the treatment of severe asthma & chronic obstructive pulmonary disease.

                          Product Name : WIN378

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          January 10, 2025

                          Lead Product(s) : HBM-9378

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase I

                          Sponsor : OrbiMed

                          Deal Size : $200.0 million

                          Deal Type : Series A Financing

                          blank